Accolade Stock News

Within the last quarter, Accolade (NASDAQ:ACCD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 0 1 0 Last 30D 0

Upgrades Tudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $0.41 in the fourth quarter, compared to $0.02 in the year-ago quarter. At the moment, the st

Upgrades According to Wolfe Research, the prior rating for Cullen/Frost Bankers Inc (NYSE:CFR) was changed from Underperform to Outperform. For the fourth quarter, Cullen/Frost Bankers had an EPS of $

Accolade (NASDAQ:ACCD) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 0 1

Accolade (NASDAQ: ACCD ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 1 0 0 0 These 5 analysts have an average price target of $31.8 versus the current price of Accolade at $16.295, implying upside. Below is a summary of how these 5 analysts rated Accolade over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the … Full story available on Benzinga.com

SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, will participate in the 2022 SVB Leerink Globa

SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, will participate in the 2022 SVB Leerink Global

Over the past 3 months, 5 analysts have published their opinion on Accolade (NASDAQ:ACCD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compan

Over the past 3 months, 5 analysts have published their opinion on Accolade (NASDAQ: ACCD ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 1 0 0 0 0 These 5 analysts have an average price target of $31.8 versus the current price of Accolade at $21.51, implying upside. Below is a summary of how these 5 analysts rated Accolade over the past 3 months. The greater the number of bullish … Full story available on Benzinga.com

Baron Funds, an asset management firm, published its Baron Discovery Fund fourth quarter 2021 investor letter a copy of which can be downloaded here.

Accolade Inc (ACCD) shares closed today 13.1% lower than it did at the end of yesterday. The stock is currently down 19.5% year-to-date, down 54.0% over the past 12 months, and down 28.5% over the past five years. Today, the Dow Jones Industrial Average rose 0.1%, and the S&P 500 rose 0.3%. Trading Activity Shares traded as high as $24.95 and as low as $18.72 this week.Shares closed 64.6% below its 52-week high and 13.4% above its 52-week low.Trading volume this week was 224.5% higher than the 10-day average and 445.7% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Information Technology industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3494.7% The company's stock price performance over the past 12 months lags the peer average by 142.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Companies in The News Are: ACCD,PACB,BIG,ILMN

SEATTLE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, will participate in 24th Annual Needham Growth

Gainers TSR, Inc. (NASDAQ: TSRI ) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year. Accolade, Inc. (NASDAQ: ACCD ) gained 27.3% to $24.36 after the company reported Q3 earnings results and raised FY22 sales guidance. Nuverra Environmental Solutions, Inc. (NYSE: NES ) shares jumped 22.6% to $2.8450. BARK, Inc. (NYSE: BARK ) gained 18% to $4.25. The company said it expects Q3 sales of $140 million, versus analysts’ estimates of $137.3 million. BARK co-founder and executive chairman Matt Meeker will cecome CEO. Nutriband Inc. (NASDAQ: NTRB ) jumped 17.2% to $7.08. Nutriband and Kindeva Drug Delivery, on Monday, signed a feasibility agreement to develop AVERSA Fentanyl, an abuse deterrent fentanyl patch. Veru Inc. (NASDAQ: VERU ) surged 17% to $6.25. Veru, on Monday, said that its Enobosarm was granted fast track designation by the FDA. Cingulate Inc. (NASDAQ: CING ) jumped 15% to $2.82. Aegis Capital initiated coverage on Cingulate with a Buy rating and announced a price target of $9.

Shares of Accolade Inc (NASDAQ: ACCD) opened about 25% up on Tuesday after the software and technology company reported better-than-expected financial results for its third quarter last night. Q3 resu